[{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"BioCorRx","sponsor":"IRISYS, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Irisys to Manufacture BioCorRx's Opioid Use Disorder Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Receives FDA Clearance of IND Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, for Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Societal CDMO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$9.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by BioCorRx
The funding helps BioCorRx to focus on the clinical development of BICX104 (naltrexone) a biodegradable, long-acting subcutaneous pellet in combination with Bupropion. It is currently evaluated in preclinical studies for methamphetamine use disorder.
The submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
BICX104, implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection for the treatment of opioid use disorder (OUD).
BICX104 is an eroding subcutaneous implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002. Part of this supplemental grant will be used to develop and refine systems and strategies at BioCorRx.
The BICX104 clinical study in two parallel groups of 12 randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injection.
BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD). The company submitted the IND to the FDA last month. The first-in-human clinical trial.
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed under BioCorRx Pharmaceuticals, Inc., BioCorRx’s controlled R&D subsidiary.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
